European Commission Grants AU-011 Orphan Drug Designation for Treating Uveal Melanoma

Aura Biosciences, Inc., a clinical-stage biotech company that develops a new class of virus-like drug conjugate therapies for multiple cancer indications, announced that AU-011, the first-ever VDC product candidate, has been granted Orphan Drug Designation by the European Commission for…